Drug Trial Radar · NCT06656702
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Jan 30, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense; Congressionally Directed Medical Research Programs
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
PsilocybinDrug
Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of psilocybin treatment as assessed by number of participants recruited, retained and adhere to treatmentTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.